|Bid||1,404.20 x 0|
|Ask||1,403.80 x 0|
|Day's range||1,392.40 - 1,417.40|
|52-week range||1,371.00 - 2,746.59|
|Beta (5Y monthly)||0.18|
|PE ratio (TTM)||12.42|
|Earnings date||02 Nov 2022|
|Forward dividend & yield||0.86 (6.05%)|
|Ex-dividend date||18 Aug 2022|
|1y target est||N/A|
Yahoo Finance health care correspondent Anjalee Khemlani details how the first case against pharmaceutical company GSK over its Zantac derivative was voluntarily dismissed.
The plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial has agreed to drop his case, according to his attorney and drugmakers named as defendants. Tuesday's news came days after shares of GlaxoSmithKline Plc, Sanofi SA, Pfizer Inc and Haleon Plc were hit by mounting investor concern about thousands of lawsuits claiming the drug, which U.S. regulators pulled from the market in 2020, causes cancer. The plaintiff, Joseph Bayer, alleged he developed esophageal cancer from taking over-the-counter Zantac.
Pharma group alleges breach of non-compete agreement to delay start date of departing business development official